responsible business supplement success depend ability research develop innovative medicine vaccine consumer healthcare product accessible people responsible waygsk responsible business supplement supplement gsk responsible business cover image work health business worker like head nurse jacqueline mankenda gsk report key information save child directly reach thousand approach responsible business child include alongside financial performance hard reach community annual report supplementary document photo ivy lahonsave child provide additional context detail progress responsible business commitment guide report guide navigation button dynamic link screen mode interactive pdf design help click dynamic link access pdf set view screen mode easily navigate report find main content relevant information report online exit screen mode press escape view information look use tab toolbar navigate section search pdf printerfriendly pdf use print icon navigation print document print printfriendly format precede return visitedgsk responsible business supplement content inside report approach health behaviour people planet ata summary assurance learn approach find develop read learn create find manage read key datum responsible business innovative product embed value inspire supportive work environmental impact embed business improve access healthcare business environment encourage operation product patient world include way employee develop life cycle reduce research develop sell capability achieve carbon emission water use market product good waste chairmans statement approach approach approach approach datum summary ceo statement open innovation ethical conduct protect health carbon summary assurance wellbee people statement responsible business develop vaccine promote value sale water practice not need keep cold marketing practice promote inclusion report waste diversity commitment well access medicine transparency vaccine clinical research community volunteering create change building product well rigorous patient meet need consumer safety reduce child mortality minimise animal testing strengthen healthcare address human infrastructure right impact eliminate control ethical interaction neglect tropical disease fight malaria eradicate polio access antiretroviral treatment hiv gsk responsible business supplement chairman statement gsk longstanding commitment responsible board continue monitor gsk external benchmarking business remain central company benchmark commitment responsible strategy reflect effort business practice gsk top improve corporate reporting access medicine index fourth top index integrate information responsible consecutive time index measure time begin business approach performance performance pharmaceutical annual report document responsible company effort improve access rejoin dow jones business supplement provide additional detail medicine healthcare develop sustainability index topic structure clearly country company reentere score put set progress dow jones sustainability index rank sector responsible business commitment company sector environmental social assuring gsk operate responsibly priority environmental social governance criteria governance criterion seek responsible investor board committee particular corporate responsibility committee crc final letter chairman gsk score b retain chair crc oversight crc reason take role position cdps progress challenge range belief significant value company ftse climate disclosure responsible business area bring society time chairman leadership index seventh doubt please see change include strategy drive innovation year recognition commercial success key need disease impact progress delivery quality climate change develop world like malaria ebola company rd organisation effort improve datum disclose directly link access medicine evolution antibiotic resistance strategy commercial model couple operating way improve access medicine vaccine strong commitment shareholder return gsk remain pricing model build capacity pharmaceutical company meet change capability africa partnership remain confident gsk deliver considerable achieve carbon expectation society save child longterm value return shareholder yd eu ac r ng yw ea rer trust carbon standard committee encourage value wide society future water standard cut continue effort evolve commercial model carbon emission water use operation globally new approach compensation sale representative roll worldwide work ongoing fundamentally change member ftsegood relationship doctor customer remove perception conflict interest sir christopher gent chairmangsk responsible business supplement ceo statement despite challenge result continue look way transform look priority area good operating environment sustained commercial model new approach progress employee gender diversity progress company compensation sale representative slightly increase proportion woman strategic priority commitment roll worldwide change build management operate responsibly reform start usa track rollout preventative year ago please healthcare programme employee particularly proud progress recent healthcare practitioner customer family reach country far commitment improve access medicine satisfaction research showing gsk year see world malaria set ambitious target carbon rank usa peer group vaccine come step close water waste continue face value bring work add submit rtss candidate regulatory challenge reduce carbon footprint fully implement approval commit value chain sale commitment stop pay doctor speak vaccine available profit price propellant base inhaler product behalf instead deliver information need big carbon footprint continue grow new multichannel system meet operational water see progress address believe change use target year early cut use affordability barrier access healthcare right thing extend tiere pricing approach competitive advantage follow initiative prescription medicine ask country finally effort operate clinical trial datum transparency pay base national income early look fulfil commitment operate important deliver commit freeze vaccine price expect people value responsibly d like thank employee gavi graduating country year heart decision work partner continue support financial performance meet exceed expectation society help address challenge deliver addition commit invest million believe commitment africa year aim s issue see china year substantial achievement year wholly disappointing provide portfolio relevant product develop responsible business take significant step rectify issue innovative pricing strategy support african identify chinese business apply bring longterm sustainable rd expertise increase local manufacturing appropriate lesson operation capacity capability business benefit strengthen monitor ethical see critical public health emergency conduct give complexity sector outbreak ebola west africa challenge work global healthcare sir andrew witty demand urgent response continue face risk chief executive officer provide humanitarian support affect continue believe robust system region accelerate development place presence market improve candidate vaccine ebola unprecedented access medicine broad healthcare rate trial underwaygsk responsible business supplement approach responsible business practice approach embed create value society governance value conduct develop innovative product maximise robust governance structure commit valuesbase responsible business practice access deliver direct benefit patient place oversee approach responsible business expect employee base value back consumer successfully business oversight integrate act transparently respectfully integrity deliver profitable sustainable business core governance framework interest patient strong governance performance turn allow generate consumer leader responsible audit risk committee focus strategic priority value return shareholder embed culture decision make key business risk area gsk include non reinv business wide society benefit work range way underpin healthy people communitie financial risk support audit conduct research approach sale assurance team provide independent view essential building strong sustainable society marketing way interact responsible business approach ie assurance senior management patient doctor policymaker contribute significant value make board risk manage continually direct indirect economic contribution group line agree assurance plan code conduct accompany listening stakeholder country community operate training seek ensure gsk gsk boardlevel corporate tax employment people understand value practice well understand responsibility committee crc lead charitable support encourage employee report chairman crc oversight expectation concern speak channel responsible business priority approach responsible business extend high standard supplier prioritie responsible business area focus meet time year provide party code conduct approach sit context macroeconomic highlevel guidance review performance social trend impact wide society progress commitment company trend present opportunity challenge global healthcare company like gsk governance structure system report progress area health board behaviour people planet chairman executive director independent develop longerterm commitment nonexecutive director area report detail progress commitment corporate corporate administration audit risk remuneration nomination responsibility finance transaction committee committee committee committee committee committeeour approach responsible business practice continue listen stakeholder ongoing stakeholder engagement value engagement range external carry additional research determine stakeholder effective tool gain current emerge issue help shape deep insight societal trend approach responsible business expectation offer example undertake formal opportunity challenge assumption materiality analysis gather internal way work external perspective key area team gsk engage wide range considerable financial operational andor stakeholder daytoday interaction reputational impact company chart customer formal engagement government right identify issue patient advocacy group relevant business focus effort regular dialogue supplier high medium importance partner investor communicate gsk stakeholder employee respond feedback critical running business effectively help retain talented people willing fundamentally change way thing well meet stakeholder expectation example include open innovation strategy stimulate research unmet medical need end low medium high direct payment doctor change way reward people sredlohekat ot ecnatropmi gsk responsible business supplement prioritise material issue access healthcare ethical conduct transparency prod uct innovation clinical trial conduct r esponsible sale marketing intellectual property right lobbying advocacy practice product safety quality energy climate change tax community investment diversity inclusion economic animal research anticounterfeite contribution training development waste recycling privacy datum security water use human right labour ethical supplier standard talent attraction reward health safety wellbee biodiversity security supply importance business successcommitment progress user key work track progressing complete work need work ongoing able demonstrate clear commitment commitment schedule deliverable good progress complete complete commitment progress find commitment tracker progress lla rof htlaeh gsk responsible business supplement commitment aim address global health need align strategic priority value open innovation adapt open innovation rd model currently disease create world open lab noncommunicable disease africa develop world apply area great unmet medical need work pharmaceutical company academic conduct scientific challenge include infectious disease alzheimer disease major study dementia research continue work imis new drug bad bug collaboration relate antibiotic research develop vaccine invest development vaccine not require continuous refrigeration invest million research enable critical liquid component not need make distribution easy expensive malaria vaccine candidate remain stable hotter climate work keep cold bill melinda gates foundation well access embe flexible pricing strategy innovative business model extend tiere pricing approach prescription medicine vaccine page medicine prescription medicine vaccine increase usage able asking country pay base wealth ability pay commit freeze vaccine access afford product vaccine price gavi graduating country year building product continue build core range product format well meet need work partner develop inhaled form oxytocin prevent well meet need people globe include able access afford woman die pregnancyrelate cause reformulate antiseptic product mouthwash reduce newborn death reduce child continue invest innovative crosssector partnership reduce child mortality continue partnership save child aim reach million mortality child match employee fundraise million launch second health innovation award obtain ema agreement pathway chlorhexidine gel establish emergency response workstream strengthen continue work partner support development strengthen reinveste million profit develop country strengthen healthcare healthcare infrastructure anticipate improve access healthcare healthcare system partner world health organisation infrastructure million underserved people vs international telecommunication union vodafone barclays pilot innovative healthcare delivery system eliminate help eliminate control neglect tropical disease affect billion donate million albendazole tablet help eliminate lf control control neglect people include elimination lymphatic filariasis intestinal worm progress identify preclinical candidate tropical disease continue investment rd ongoing product donation contribution combat leishmaniasis parasite collaboration university london declaration neglect tropical disease dundee wellcome trust fight malaria build year commitment contribute fight malaria file world malaria vaccine candidate rtss regulatory approval continue rd investment partnership ground start phase iii trial tafenoquine treat p vivax malariacommitment progress continue user key progress find commitment tracker progress eradicate polio continue support objective eradicating polio providing deliver million dose oral polio vaccine global polio eradication vaccine unicef achieve initiative country need bring total billion dose past year access viiv healthcare continue increase access medicine care enter agreement medicine patent pool accelerate access antiretroviral adult child live hiv world help dolutegravir adult child country hiv burden treatment hiv unaid achieve goal reach million people globally high antiretroviral treatment ruoivaheb ruo gsk responsible business supplement work track progressing complete work need work ongoing able demonstrate clear commitment commitment schedule deliverable good progress complete complete commitment promote value continue drive valuesbased approach sale marketing practice complete rollout new sale compensation model globally january sale marketing world interest consumer patient core start work change engage healthcare professional practice long pay speak medicine change way support education doctor transparency transparent possible clinical trial datum include publishing lead development wwwclinicalstudydatarequestcom researcher clinical trial datum clinical study report patientlevel datum outcome trial medicine request access anonymise patient level data clinical trial conduct gsk appropriate process make available gsk company researcher access anonymised patient level datum scientific enquiry rigorous patient continue ensure interest safety patient consumer develop party oversight programme consolidate streamline consumer safety paramount importance way design undertake clinical trial approach manage thirdparty risk globally introduce fingerprint product quality assurance monitoring report adverse endtoend supply chain serialisation programme strengthen event ongoing product usage anticounterfeite measure minimise animal rigorously challenge need animal study work minimise impact launch strategic initiative potential reduce reliance animal testing animal welfare invest development alternative study share study continue look new way develop medicine human cell animalbase data tissue european bioinformatics institute sanger institute promote human address un guiding principle business human right increase focus human right impact identify external assessment right operation supplier relationship business example global party oversight programme engage patient demonstrate gsk interaction patient advocacy group political enhance global standard operating procedure public policy group advocacy group stakeholder conduct appropriately ethically transparently government official engagement year implementation emerge market political stakeholder australasia patient advocacy strategy broaden deepen interaction patient group whilst embed high level transparency governancecommitment progress continue user key progress find commitment tracker progress protect health continue create work environment inspire people grow provide preventive healthcare employee family wellbee perform healthy resilient way country employee participate programme improve people personal resilience injury illness rate elpoep ruo promote inclusion continue promote inclusion diversity globally gsk increase proportion woman management develop diversity global standard measure business disability performance community extend volunteering opportunity bring positive change community employee volunteer nonprofit organisation pulse volunteer global health provide individual development programme establish volunteer ambassador network country create change develop locally relevant programme tenalp ruo gsk responsible business supplement work track progressing complete work need work ongoing able demonstrate clear commitment commitment schedule deliverable good progress complete complete commitment aim carbon reduce overall carbon footprint vs carbon cut scope emission operation neutral neutral value chain scope emission remain challenge sale propellant base inhaler continue grow reduce water reduce water impact value chain vs cut operational water use hit impact target year early complete fouryear assessment measure water impact value chain recertifie carbon trust water standard reduce waste reduce operational waste vs generate tonne waste operation send waste landfill compare site achieve zero waste landfill building build sustainable supply line nutrition portfolio work local farmer remain committed build sustainable supply chain nutrition sustainability improve agricultural practice improve yield competitiveness review portfolio change market dynamic portfolio impact supply chain livelihood source model currently review commitmentgsk responsible business supplement h ealth konnah family live community near monrovia badly affect ebola konnah lose family member virus remain family help save child gsk contribute fight ebola accelerate development investigational vaccine support humanitarian effort include fund save child enable continue work change protect identitygsk responsible business supplement health approach health challenge remain medicine vaccine consumer health improve access availability product improve quality life patient aim extend access exist product focus contribution fundamental barrier consumer world million tackle affordability availability barrier fight ebola economic development people get vaccine tiere pricing approach prescription treatment need afford gsk work closely world quality life gsk medicine vaccine country pay disease health organization regulator different price base ability pay aim real treatment impact poor partner respond ebola crisis determine gross national income gni country continue underresourced accelerate development investigational contribution meeting health system caput maximise patient benefit sustain ebola vaccine contribute business develop country challenge play tackle global health ldc cap price overall humanitarian effort challenge open innovation develop country february investigational ebola target unmet medical need pioneer new invest new formulation distribution vaccine test large phase iii business model increase access model product available clinical trial sponsor national institute product collaborate strengthen health nih liberia protect volunteer develop country bear great burden healthcare infrastructure hope contribute significantly infectious noncommunicable disease make important contribution control outbreak future use mass ncds resource manage millennium development goal vaccination campaign depend africa global health regulator stakeholder innovation challenge magnify invest satisfied vaccine candidate provide gsk scientist create new product million stimulate research improve protection ebola cause potential real difference scientific capability build manufacture significant effect quickly large people live new molecular capacity quantity vaccine entity phase ii phase iii development strengthen healthcare system follow approval receive actively explore relevant world poor country lack significant product approval organisation partner opportunitie train healthcare worker diagnose disease respiratory hiv diabetes accelerate development manufacturing administer treatment prevent industrial scale trial know not discover patient access medicine successful position significantly collaborate partner vaccine regardless cost rampup production vaccine candidate target unmet medical need great reinvesting profit ldc train help combat future ebola outbreak scientific challenge disease frontline healthcare worker aim improve impact develop world alzheimer access healthcare million people antibiotic resistance healthcare worker adapt approach intellectual partner train past year property accelerate discovery new drug provide access healthcare press health priority malaria million people tb open innovation strategy offer external scientist access compound library resource promote research areasgsk responsible business supplement health approach continue invest africa gsk investing africa increase access goal deliver highimpact research project medicine build capacity deliver sustainable contribute world health organisation global growth vision gsk product available target reduction preventable ncd death population subsaharan africa ncd open lab build success ldc original open lab spain focus malaria tuberculosis tb tropical disease africa long bear high rate infectious disease face grow incidence ncds dual health burden pose significant trust science africa programme obstacle economic social development continue seek good scientific idea fund development award funding invest million africa scientist kenya uganda research hiv year work partner aim provide tb ncds africa website portfolio relevant product innovative pricing trust science africa latin america strategy support african rd expertise increase local manufacturing capacity capability develop product need increase capability capacity manufacture support open innovation collaboration medicine africa create job boost longterm invest million create world economic prospect invest million africa open lab ncd research gsk expand exist facility kenya nigeria scientist external researcher work build new factory ensure sustainable improve understand ncd variation production medicine africa african people african patient increase region skill base aim establish academic chairsprogramme promote study pharmaceutical science healthcare policy provision time enhance local research manufacturing healthcare capability help secure future investment build vibrant healthcare economiesgsk responsible business supplement health open innovation adapt innovation open innovation process noncommunicable disease ncds urgent need develop new antibiotic accelerate research treatment disease claim life ncds cancer effectively target bacteria widely model aim stimulate develop world accept heart disease respiratory problem kidney recognise unique scientific challenge research need potential commercial return disease diabete world big lengthy complex clinical trial low rd investment apply killers strategic approach ncds include return investment hamper attempt open innovation model target unmet innovation research new drug improve address need company medical need overcome significant scientific efficacy exist medicine increase withdraw area combine challenge alzheimer antibiotic patient access medicine health long heritage expertise antibiotic education prevention product open innovation approach stimulate open innovation approach commitment adapt open innovation help people quit smoking example research antibiotic resistance approach base principle rd model currently disease approach ncds policy paper advocate global action access compound datum great develop world apply area open innovation approach flexibility intellectual property inhouse team researcher great unmet medical need scientific promote research new treatment ncds partnership share expertise process investigate potential new antibiotic challenge include infectious disease alzheimer disease infrastructure nearly ncdrelate premature death collaborate innovative occur low middleincome country medicine initiative imis new drug bad screened entire library march africa strategy bugs ndbb programme million compound sign activity announce million investment establish malaria tb world contribute project progress overview progress world africa ncd open lab address deadly infectious disease share ndbb programme range design specific variation ncds africa compounds datum wide scientific implementation efficient clinical trial innovative research network gsk scientist community stimulate research area understand design compound collaborate researcher africa high aim share result similar penetrate multidrugresistant pathogen quality research hub rd facility screen exercise neglect stevenage uk gsk medical research alzheimer dementia tropical disease near future council south africa uk extend open innovation approach external researcher work alongside gsk pledge million help south african target alzheimer dementia gsk scientist open lab tre canto researcher study ncds open dementia platform uk million spain access compound library lab initiative proposal partnership pharmaceutical company facility financial support tre november commit million academic conduct large study canto open lab foundation independent support successful proposal ncd research dementia research collaboration focus charity million funding gsk cameroon cte divoire ghana kenya develop treatment early project open lab focus disease malawi nigeria gambia uganda detection prevention disease develop world visit tackle antibiotic resistance work identify indicator scientist use open lab discovery antibiotic revolutionise alzheimer disease participation build portfolio research project modern medicine patient long die accelerate medicine partnership establish minor infection efficacy medical national institutes health peer company mainstay increasingly threaten steady academic rise bacteria immune antibiotic antibioticresistant bacteria mrsa cause death year eu alonegsk responsible business supplement health develop vaccine not need keep cold work partner vaccine need keep cold explore number different sure degrade transport approach ultimate target help overcome barrier storage keeping refrigerate step vaccine stable year c deliver vaccine way tremendous challenge particularly approach consider develop country vaccine play spray dry approach extensively develop country important role food manufacturing previously manufacture vaccine work inadequate equipment unreliable power bill melinda gates foundation supply lack resource monitor vaccine discovery partnership temperature difficult maintain invest million research enable cold chain vaccine gsk adjuvant critical liquid component commitment invest development recipient cold chain begin rtss candidate malaria vaccine remain vaccine not require continuous manufacturing plant vaccine stable high temperature eventually refrigeration make distribution easier transfer destination country easy transport vaccine expensive refrigerated unit arrival subsaharan african region disease challenge transfer vaccine prevalent involve cool box take boat malaria vaccine remote islands donkey small village progress overview progress mountain reduce dependence good progress cold chain big step forward objective currently evaluate delivery sustainable vaccination programme finding incorporated development future vaccine include candidate tb vaccinegsk responsible business supplement health well access medicine vaccine want medicine improve access healthcare reserve low vaccine price catch programme strategy address affordability build local gavi publicprivate alliance improve access product approve europe usa vaccines accessible capacity support vulnerable community vaccine world poor country seek approval develop country need gavi support country gni head significant unmet medical need affordability country develop appropriate permit matter live improve affordability tiere pricing exceed gni threshold graduate national regulation combat rise strategy enable offer product afford gavi support commit freeze prevalence respiratory disease price account economic factor vaccine price graduate country chronic obstructive pulmonary disease copd country year help maintain commitment asthma make nonpatente mean ask country pay fair price immunisation transition establish medicine ventolin medicine vaccine base flixotide newly launch patent commit provide gavi wealth determine gross national income medicine relvar anoro million vaccine dose reduce commitment embed flexible gni capita enable broad access affordable help achieve goal price help protect million child pricing strategy innovative business product globally price increase access respiratory medicine develop world supply gavi model prescription medicine develop country ldc represent relevant patient develop country vaccine rotavirus rotarix pneumococcal vaccine increase usage low tier additional tier define disease synflorix cervical cancer middle income country national income able access afford product low upper middle high income cervarix cervarix gavi high significant portion country onesizefitsall demonstration project african country population afford medicine approach tier allow country understand effective way immunise tiere pricing approach mean unit develop local pricing strategy progress overview progress girl enter threeyear offer innovative patient access programme account economic factor country agreement supply lowcost dose example india introduce programme healthcare system patient affordability synflorix vaccine mdecin san frontire offer eligible patient suffer commit extend tiere immunise child catch ongoing crisis chronic idiopathic thrombocytopenic purpura pricing approach include prescription continue work pan american autoimmune condition week medicine vaccine health organization bill melinda treatment free charge receive cap price patent medicine gate foundation supply cervarix country week course revolade vaccine ldc price charge latin america caribbean lower develop country long price support longterm vaccination manufacturing cost cover programme cervical cancer sustain price long term adopt approach increase medicine supply ldc yemen example reduce price medicine average sale volume increase gsk responsible business supplement health well access medicine vaccine continue develop market important building local capability capacity support include mindful burden healthcare cost promote local manufacturing developing give cash donate million europe tailor approach specific country joint venture technology cash improve health wellbee country need work government transfer arrangement help build capability community worldwide example demonstrate value patient payer develop country research donate million strengthen cash healthcare professional taxpayer manufacture vaccine medicine product healthcare infrastructure ldc primarily industry example uk price increase access market inkind respiratory medicine anoro relvar incruse training community health worker time example include invest develop skill management asthma copd line infrastructure rd manufacturing capability alternative usa list price product donation donate medicine total new africa strategy newly launch diabete medicine tanzeum value million support include low medicine class brazil partner fiocruz lead patient assistance programme public health research institution manufacture account total giving offer patient assistance programme vaccine address country public health million albendazole tablet pap eligible patient priority develop vaccine dengue fever fight lymphatic filariasis soiltransmitte insurance pap provide helminth product donation prescribe gsk medicine vaccine value india joint venture biological e support humanitarian aid country million million nearly indian biotechnology company develop distribute partner americare patient overall patient enrolment decline sixinone combination vaccine contain direct relief m world health map gsk patient assistance programme primarily inactivated poliovirus vaccine ipv international project hope result new coverage option available support vulnerable community patient affordable care act time encourage employee improve access healthcare people new coverage option gsk volunteer time expertise vulnerable community targeted continue help support patient access employee volunteering time account product financial donation programme medicine provide service help million run local global partner design interested potentially eligible enrollee sustainable long term understand alternative coverage option global community investment total million million compare million million overall total contribution represent decline largely few patient enrol gsk patient assistance programme primarily result affordable care act gsk value product donation cost good believe truer reflection cost gsk wholesale acquisition cost pharma industry value product donation total value product donation base wholesale acquisition cost milliongsk responsible business supplement health building product well meet need aim well meet improve access product develop country risk woman die india lowincome rural making affordable make pregnancyrelate cause time consumer live hardtoreach place need people worldwide sure right type product available high develop economy significantly expand distribution network develop new product right place meet patient need single big cause death excessive cover village directly bleed oxytocin manufacture hormone range wellness oral health nutritional formulation format continue develop new format stop bleed product appropriate size price range medicine consumer product require refrigeration train healthcare everyday purchase consumption middleincome patient live worker administer product train local woman set respiratory condition asthma lack resourcepoor country business sell product household copd afford sophisticated multidose launch multisector partnership develop area retailer inhaler create new inhaler product inhale form oxytocin design commitment continue build core launch singleserve sachet singledose capsule ventolin rotacap heatstable affordable easy administer range product format well sensodyne toothpaste philippine sell small pack size spread meet need people globe reduce newborn death accelerate usa offer small oneweek supply cost ventolin rotacap widely include able access development common antiseptic find number smoke cessation product distribute gsk product philippine afford product corsodyl mouthwash prevent umbilical develop similar singledose cord infection lead sepsis capsule respiratory partnership save child medicine seretide progress overview track viiv healthcare begin new collaboration janssen develop twodrug singletablet regimen patient virally suppress threedrug regimen plan include investigate potential paediatric fixeddose formulation regiman gsk responsible business supplement health reduce child mortality innovative partnership global effort tackle child mortality june launch second annual medicine recommended halve death rate underfive million healthcare innovation award paediatric use include treatment asthma aim save life million child die save child identify innovation cancer eczema epilepsy hivaid child increase fifth birthday improve survival rate child infectious disease albendazole tablet low middleincome country mainly newborn particular develop country donation support s goal access essential vaccine preventable disease organisation jointly award deworm schoolage child medicine prize university country intestinal worm endemic vaccine medicine consumer healthcare nairobi receive recognition barcode building commitment product expertise play important wellness card register baby paediatric hiv viiv healthcare actively role reduce child mortality clinic bear encourage carer investigate childfriendly formulation partner save million life vaccination ongoing care dolutegravir add number partner save child add credit food product visit medicine available child live hiv commitment continue invest combine scientific expertise global clinic colalife base zambia information innovative crosssector partnership reach charitys child health expertise recognise innovative business model reduce child mortality ontheground knowledge break lastmile barrier aim help save life million access medicine remote area child world poor country gsk employee contribute time progress overview track partnership form explore expertise enthusiasm support exist product chlorhexidine partnership save child reduce death infant volunteer fundraising match reformulate antiseptic employee fundraise million year corsodyl mouthwash umbilical cord care million reach september prevent infection common cause fund raise employee death newborn support programme pilot innovative approach improve care invest flagship programme premature baby kenya democratic republic congo drc kenya aim tackle challenge immunise treat child supply demand effective healthcare world child contribute reduction maternal newborn immunise disease underfive death programme focus gsk vaccine supply vaccine strengthen local health facility gavi significantly reduce price use service capacity building frontline world poor country health worker community mobilisation commit provide gavi complete catch vaccination million vaccine dose reduce programme drc child price help protect million child hardtoreach rural area develop world photo jonathan hyamssave childrengsk responsible business supplement health strengthen healthcare infrastructure gsk commit partner training project undertake include child mozambique healthcare worker explore innovative register mvaccination pilot strengthen health training nurse innovative distance delivery model improve access programme vodafone seek elearne tanzania amref health africa system improve healthcare million people improve vaccination rate mobile phone advocacy initiative save child mobile app remind caregiver access healthcare reinveste healthcare focus ministry health official vaccine enable government reinvest profit sale develop country pharmaceutical consumer healthcare member parliament burkina faso healthcare worker well manage vaccine stock vaccination visit product ldc strengthen training health worker care record complete healthcare system invest million international rural bangladesh reach initial research clinic expand base profit total million beneficiary service clinic oneyear pilot million reinvestment gsk support million community fund usaid gavi programme begin commitment continue work partner health worker campaign lead un pilot measure impact assess cost support strengthen healthcare training key focus chronic shortage sustainable development network train effectiveness inform decision scale infrastructure anticipate train healthcare worker main million community health worker end programme mozambique improve access healthcare million barrier provide effective healthcare investment help track progress african country underserve people vs remote region work partner goal virtual operation mobile technology heart major amref health africa care international room enable user share good collaboration join save child train practice success challenge international telecommunication union frontline healthcare worker far ldc progress overview progress partnering develop new healthcare combat ncds world well health africa asia caribbean delivery model information education preventive measure community health worker doctor midwive explore way improve access play essential role reduce global nurse volunteer turn reach healthcare promote economic development incidence ncds address common million people example million threeyear risk factor include smoke alcohol poor diet reinvestment programme partnership barclays zambia year inactivity health ncds develop work partner educate community finalise plan test feasibility scale good practice online healthcare health work government new social enterprise model increase include reminder support patient advocate investment healthcare availability health service product tip avoid risk factor technical support website summary reinvestment underserved region plan pilot healthcare provider programmes country micro health insurance product improve affordability essential medicinesgsk responsible business supplement health eliminate control neglect tropical disease commit ntds affect billion people albendazole donation research new treatment world poor community cause gsk donate billion urgent need new treatment combat defeat neglect tropical disability disfiguration death stretch albendazole tablet help eliminate lf ntds require flexible open approach disease ntds free healthcare budget severely constrain control intestinal worm past year innovation gsk found member wipo development opportunity donation reach million research open innovation platform future generation people include million child seeks accelerate development new extensive burden ntds require debilitate impact country complete mass drug well treatment ntds dengue coordinate response improve access administration campaign lf researcher rabie chagas disease malaria exist treatment stimulate research estimate number people risk infection tb currently exist gsk partner lf halve london declaration join bill melinda research development facility tre gate foundation pharmaceutical million people infect lf canto spain prioritise research company donor national government million live pain stigma ntds disease develop commitment help eliminate control commitment work control debilitate swelling cause intestinal world research yield ntds affect billion people eliminate ntds worm infect million child worldwide include elimination progress identify preclinical lead work mile supply symptom stunt development lymphatic filariasis lf candidate combat leishmaniasis parasite chain ensure efficient forecasting manufacturing prevent go school continue investment rd ongoing collaboration university shipping donate product annual product donation contribution donate albendazole tablet dundee wellcome trust scorecard detail progress london declaration ntds support effort eliminate lf country london declaration partner highquality hit african contribute s goal regularly trypanosomiasis sleep sickness focus contribution deworm schoolage child screen million compound big difference product donation country intestinal worm endemic progress overview progress gsk compound library albendazole target lf soiltransmitte donate million albendazole helminth intestinal worm use tablet lf elimination million tablet promise hit compound library open innovation strategy promote research treat intestinal worm chagas disease identify open new treatment ntds lab collaboration new york university take forward stage total drug discovery process albendazole tablet donation set compound assemble tablet lf elimination ntds available tablet treat intestinal worm wide scientific community rd total gsk responsible business supplement health fighting malaria support malaria responsible gsk invest hundred million dollar promote preventive measure death year billion people date rtss programme receive african malaria partnership fight malaria risk spread mosquito estimate funding bill melinda gates foundation invest million year research new death malaria occur subsaharan africa addition international nonprofit organisation support community programme ssa child path contribute financial scientific managerial aim prevent malaria training health worker treatment promote age field expertise development rtss volunteer distribute insecticidetreate preventive measure date license vaccine available gsk commit set eventual price bed net promote awareness campaign prevention malaria gsk reach major rtss profit price cover cost work nonprofit partner deliver treat bed net milestone submission regulatory manufacturing vaccine small support ground community sub application candidate malaria vaccine return reinveste rd saharan africa rtss european medicine agency ema second generation malaria vaccine vaccines sierra leone example work tropical disease key moment gsk year journey tony blair faith foundation reach develop world malaria vaccine research new treatment million people population commitment build year submission follow announcement addition work vaccine prevent train religious leader turn train commitment contribute fight phase iii datum show rtss halve spread malaria explore effective community volunteer malaria prevention malaria continue rd investment number case clinical malaria young treatment contract disease estimate household child aged month vaccination partnership ground change behaviour result gsk pulse gsk researcher work collaboration month vaccination volunteer explore opportunity replicate medicine malaria venture mmv positive opinion ema grant develop tafenoquine singledose medicine model parts africa indicate policy recommendation progress overview progress treatment p vivax malaria strain longstanding partnership carter possible end positive widespread south south east asia latin center nigeria provide insecticidetreated bed opinion ema basis marketing america horn africa late stage net educate people use authorisation application ssa tafenoquine clinical trial announce effectively tackle malaria lf rtss development involve big april assess drug efficacy transmit mosquito ghana support vaccine trial conduct africa safety adult patient successful tafenoquine family health international fhi training number additional step need contribute significantly eliminate community health worker volunteer complete anticipate vaccine malaria prevent relapse dormant diagnosis treatment management malaria available implementation early adopter p vivax parasite ntds onchocerciasis ssa country schistosomiasis intestinal worm work project find new drug p falciparum malaria treatment approach phase preclinical discovery development end gsk responsible business supplement health eradicating polio gsk play key role war polio lead global polio opv contain small quantity weaken eradication initiative gpei eradicate live polio virus phase country read online tackle polio past disease country cut global polio eradicate year remain incidence rate past year prevent small risk disease publish detail online key reemerge vaccine instead commit support eliminate final proving extremely issue include country administer inactivated polio challenge india declare poliofree s goal completely vaccine ipv ensure longterm supply clinical trial develop world milestone global health expert eradicate disease enn dce e mth ico u ing h f gu hn aa nc ih si te av na b nle ig eb ru iat p ano dlio p r ae km isa ti ns io nf ap nl eio w v ipc vci n fae cs l iw tye na r vv es bin eg l g iu wm hil elio ren tee cv nl oo lp oi gng tw rao nr sld fe v raccine production production begin new outbreak africa ip access medicine middle east produce supply ipv develop country develop country explore way vaccine recognise pandemic preparedness develop accessible affordable vital eradication effort country commitment continue support develop country joint venture deliver million dose oral objective eradicate polio biological e indian pharmaceutical technology transfer capacity building polio vaccine opv gpei country provide vaccine unicef company create combination vaccine develop country need contribute achieve include ipv vaccine billion dose expect work health mother meet unicef demand disease single dose expect child available anticipate billion dose gsk briefing noncommunicable disease progress overview track stockpile large amount develop world opv keep available use unicef gsk position statement post event outbreak development agenda approach pricing product donation work health mother childrengsk responsible business supplement health access antiretroviral treatment hiv contribute global effort include important contribution viiv healthcare conduct collaborative child generic manufacturer viiv healthcare help reduce research trial subsaharan africa assess royaltyfree voluntary licence develop paediatric global effort tackle hiv infection rate treat people live hiv formulation dolutegravir country hivaids viiv aidsrelated death resource scarce include issue child hiv live licence million people worldwide mothertochild hiv transmission paediatric include paediatric formulation lowerdose healthcare specialist live hiv million die adult treatment strategy implication tablet currently clinical development hiv company own aidsrelated cause hiv hepatitis b tuberculosis coinfection improve outcome key affected deliver new treatment increase access hiv treatment care population gsk pfizer shionogi viiv healthcare grant approval nearly people infect hiv live vulnerable marginalised population eu innovative antiretroviral treatment lowincome country increase access care sex worker man sex tivicay tivicay brand compound treatment priority viiv healthcare apply man imperative access therapy dolutegravir integrase inhibitor uniform approach medicine care combine support community combination antiretroviral medicinal goal support people country base service combat stigma provide commitment viiv healthcare product treatment adult affect hiv royaltyfree voluntary licence support viiv healthcare work continue research new treatment adolescent live hiv trial show offer lowincome leastdevelope partner positive action initiative increase access medicine care tivicay effective treatmentnave subsaharan african country middleincome meet need community adult child live hiv experienced patient cite country apply flexible pricing policy vulnerable group million world work community dolutegravir longterm developmental factor gross domestic product impact child live hiv combat stigma discrimination associate priority child antiretroviral treatment epidemic country subsaharan africa hiv help world health combine antiretroviral single pill fourteen royaltyfree licence agreement access appropriate treatment treat organization unaid achieve improve convenience patient generic manufacturing company enable child require appropriate formulation goal reach million people viiv healthcare secure approval usa international manufacturer produce metabolic rate feed globally antiretroviral treatment europe new singlepill treatment market lowcost version viiv habit differ adult viiv healthcare work know triumeq combine dolutegravir healthcare antiretroviral donor agency partner develop appropriate formulation nucleoside reverse transcriptase inhibitor publicsector programme low price include paediatric oral solution progress overview progress pb aa rtc na ev ri ir n gn wd il ta hm ji av nu sd sin ee n tv oi dv e h vee la olt ph c aa nr de sis tu dls month regulatory approval nd rm esa es ak cd h fl tra iv ao lsu sd es slu et dio n p e tric twodrug single tablet combine dolutegravir viiv healthcare enter agreement adolescent patient worldwide rilpivirine nonnucleoside reverse medicine patent pool mpp accelerate transcriptase inhibitor patient access dolutegravir adult past year viiv healthcare virally suppress threedrug regimen child country hiv burden positive action child fund invest high adult viiv healthcare grant million programme second study begin royaltyfree licence leastdevelope subsaharan africa help prevent mother experimental longacte injectable integrase lowincome subsaharan african country pass hiv child million inhibitor cabotegravir know gsk introduce firstever mpp licence paediatric seed fund viiv healthcare collaborate tiere royalty structure small janssen study cabotegravir efficacy viiv healthcare website percentage price base gdp safety tolerability combine information specific middleincome country longacte form rilpivirine patient virally suppressedgsk responsible business supplement behaviour work core value patient focus integrity respect people transparency heart decision embed ethical behaviour business code conduct training speak culture include stevenage site umesh kumar worksgsk responsible business supplement behaviour approach change value ensure employee expect employee party understand expectation focus code conduct way work work act accord value aim create workplace embe value patient focus integrity respect people feels value respect empower update code reinforce transparency right decision work critical role value play protect want employee understand reputation commercial success want understand possible strengthen message employee expectation ethical behaviour exceed societys expectation feel protect empower report confidence report concern code change way business go concern confidential speak conduct available language industry norm embed channel drive enhance create resource centre tool value thirdparty oversight extend code discussion guide help link value local cover complementary workforce research practice advance medical activity culture science increase access datum training code conduct employee fail complete mandatory training clinical research trial include mandatory employee time subject disciplinary action provide researcher anonymise require complementary worker define permit local labour law patientlevel information designated manager fulfil annual sale marketing practice ethical leadership certification requirement fundamentally change compensation ensure lead example create model sale team reinforce patient ethical working environment focus business practice schedule global learning programme stop payment healthcare professional year easy employee speak behalf avoid perceive train value policy regulatory conflict interest requirement classify programme employee performance management live mandatory expect elective ensure key value clear expectation programme prioritise evaluate individual performance new performance management system gsk responsible business supplement behaviour approach continue work supplier party supplier party completion audit work supplier develop agent distributor affiliate company improvement plan address area concern check plan implement satisfactorily agree equity stake play timeframe significant gap identify suspend essential role help develop terminate work exist supplier decide manufacture distribute product work potential new supplier work party expose addition ehs audits specialist commercial insurance risk harm business company conduct seven assessment review risk supply manage risk expect party comply new companywide thirdparty oversight risk management standard quality safety ethic labour right health programme build establish standard system safety environment party code conduct currently deliver decentralise way streamline set expectation work party create standardised approach address thirdparty risk business audit team manage regularly assess performance supplier support manufacture supply supplier ehs audit exist potential supplier chain supplier assess quality compliance gsk quality management system america audit supplier ethical environmental health europe safety ehs management system performance asia increase number eh audits high risk supplier facility create new team total number audits support extensive ehs riskbase auditing supplier audit count single audit multiple siteslocation supplier base include ehs human right labour include practice audits conduct collaboration payment term pharmaceutical company pharmaceutical expect supplier meet standard supply chain initiative psci responsibility support pay time know audits datum summary small business particular face cashflow challenge follow change standard payment term supplier review term small medium company result exception small medium supplier small diverse supplier usa standard payment term set dedicated smallbusiness hotline provide advice support small suppliersgsk responsible business supplement behaviour ethical conduct prevent bribery corruption deeply disappointing matter global ethic compliance team type policy violation bribery corruption value illegal activity gskci clear manage investigation report concern business reputation risk breach gsk governance compliance provide tool oversight guidance zero tolerance approach procedure wholly contrary improve compliance form attendancepayroll value standard expect abac investigation committee oversee antibribery corruption abac code conduct employee publish statement allegation bribery corruption programme design prevent noncompliance good manufacturing continue reevaluate effectiveness io tsf pp eo ol pog ley oth ue r c weh bin se ee government g inc rk ea w ul rs io n vm ea sd tige tu ivb es cta ai pn ati bal li tyv e ost um r e gn lot bto l dpr isa tc rt ibic ue ts io ng poo rad c tices programme ensure robust employee corporate investigation team investigate local work access handbook offer practical focus learn issue regulation violation allegation misconduct include abac g tou pid ra en vc ee n ta nn od n p cro oc pd liu ar ne cs e h aa not n rc el iu nd foe r cc eo n ot ur ro ls w rece ih fya v e isk se un e st e idp es n ifi ec atp gre kn cs ii v ie nl cy lu ding fraud issue allegation raise p ra mke ot ti og n aa ln ad c tivitie number country currently policy prevent corrupt practice change engagement activity healthcare training completion follow investigate include professional expand review falsification document people work highrisk area complete poland syria lebanon monitor invoicing payment travel expense mandatory online training additional facetoface training provide relevant use robust compliance system work closely employee discipline fraud role risk face training use government continue innovate improve policy violation access medicine establish gskci dismiss agree leave realworld example help employee build model reform chinas healthcare industry company voluntarily policy violation relate skill need identify risk effectively seek apply appropriate sale marketing code account combat real perceive corruption breach external code lesson operation give dismissal total discipline gsk employee complementary gsk find breach external complex global environment employee receive document worker complete additional abac training industry government promotional code operate continue face risk warn remainder depth cover code time relate receive verbal warning conduct training reporting investigate concern consumer healthcare product mainly speak programme offer people primary reason increase number breach national regulation code dedicated independent audit outside gsk range channel voice disciplinary case particularly document advertising remain breach relate team assess internal control help concern report misconduct fear warning relate code conduct violation prescription product include breach ensure maintain ethical standard reprisal include telephone internet increase number report china promotional material advertising continue invest method channel run independent external operator strengthening investigate breach external assuring control prevent risk enable anonymous reporting concern monitor system introduction code step prevent recurrence bribery corruption investigate gsk management quarterly knowledge test sale include retrain corrective september gsk china investment representative failure pass test result measure disciplinary action standardise monitor contact co ltd gskci find guilty according employee receive document warning global compliance management chinese law bribe nongovernment system report potential allegation ask employee remain company follow personnel verdict follow investigation question significantly increase policy violation receive retrain increase initiate chinas ministry public security monitoring activity globally lead monitor support case retrain june include fine million increase contact extended employee colleague prevent contact make similar mistakesgsk responsible business supplement behaviour promote value sale marketing practice transform create sale force put patient secondly change support directtoconsumer marketing need education doctor commitment prescription medicine way compensate modernise way sell market medical education remain unchanged advertise prescription medicine sale representative medicine transform business model away direct sponsorship directly consumer new zealand industry year individual hcp arm length funding usa directtoconsumer dtc advertising engage change compensate sale example thirdparty independent medical prescription medicine permit healthcare professional representative engage healthcare organisation organisation market dtc advertising govern professional hcp meet customer need decide good deliver education dtc communication policy base ensure patient interest come programme influence gsk phrma guide principle direct consumer good progress advertisement prescription medicine thirdly long pay hcp commitment key area announce speak prescriber medicine dtc advertising usa review december instead channel include legal regulatory medical specialist new commitment continue drive value firstly january complete digital realtime application provide dtc television advertisement submit base approach sale marketing rollout change way sale team information medicine vaccine food drug administration fda practice world interest compensate sale professional way hcp want want review comment broadcast consumer patient core world long individual sale target expert medical doctor gsk pharmaceutical business receive instead assess compensate base role talk answer question notice violation warning letter technical skill scientific knowledge medicine peer fda advertising promotion product progress overview track quality service deliver hcp responsible measured provide commercial practice policy ensure broad business performance sale team right information support safe effective sale marketing activity relate listening customer need bring use medicine pharmaceutical product meet legal right gsk resource help improve patient care continue pay hcp nonpromotional requirement high ethical standard usa gsk rank major advisory service clinical research revise policy pharmaceutical company hcp value welcome gsk transform payment govern rigorous control principlesbase userfriendly bring customer satisfaction survey business model ensure base fair market value include new criterion sale marketing employee meet launch dtc promotion new patient interest central publishing payment hcp relevant party act behalf medicine include educate hcp gsk committed publishing payment decision company take follow code practice promotion new treatment alert hcp healthcare organisation customer interaction refresh upcoming advertising campaign remove potential concern country include code align value undue gsk influence hcp australia france japan netherlands portugal slovakia uk usa line locally prescribe behaviour bold agree government industry association epf monitor closely standard continue support increase transparency country industry nicola bedlington association government establish specific secretary general european guideline disclosure example patient forum european federation pharmaceutical industry association code paymentsgsk responsible business supplement behaviour transparency clinical research sharing information give time aim provide great access researcher submit research proposal volunteer patient country information design method result independent review panel ensure clinical trial support participate nearly clinical trial trial protect personal datum responsibly secure work benefit share information trial help information participant register environment end gsk sure involvement contribute include summary trial result study list available request medical science advancement medical science patient csr follow improvement researcher able ask datum patient care care contribution help researcher design utility register study research team gsk well understand year see increase number page access datum system disease area develop new medicine view visit duration visit survey researcher experience show treatment people need company provide secure environment meeting key large information publicly researcher detail datum sit need help identify area available gsk pharmaceutical clinical trial result conduct research improvement complete audit commitment transparent possible company sign alltrial campaign create online system internal process place support clinical trial datum include publish research transparency researcher request access detailed commitment provide great access clinical study report patientlevel online clinical study register anonymise patientlevel datum trial patient level data datum outcome trial medicine available information trial january expand system conduct gsk appropriate include result summary regardless launch wwwclinicalstudydatarequestcom process make available researcher outcome consider include data company end access anonymise patientlevel datum positive negative gsk company scientific enquiry system encourage development gsk company independent system include study clinical study report csrs formal report industry academia form basis submission regulatory progress overview progress agency publicly available csr post register personal information remove cole initiative nonprofit organisation transcelerate biopharma inc develop recommend approach remove redact personal information csrsgsk responsible business supplement behaviour rigorous patient consumer safety patient safety medicine potential risk collaborate industry peer regulator conduct trial accordance benefit identify evaluate healthcare provider patient interested international conference harmonisation number priority safety concern ensure risk party improve communication good clinical practice guideline trial development testing clearly communicate patient prescriber medicine enhance pharmacovigilance protocol review independent ethic payer regulator science relate detection monitor committee medical professional manufacturing use assessment understand prevention scientist lay people investigator robust policy governance framework product adverse effect drugrelate power reject stop clinical trial help detect act adverse effect problem effort improve pilot riskbase monitoring associate medicine pharmacovigilance process research team approach use new technique identify apply computerised statistical tool perform benefitrisk evaluation manage emerge risk associate data analyse safety information example life cycle medicine result quality patient safety plan implement identify unexpected adverse event present global safety board approach clinical trial report disproportionate basis commitment continue ensure replace multiple departmentspecific tool maintain global risk register share interest safety patient consumer gsk global safety board chair new global database improve global risk emerge clinical trial paramount importance way chief medical officer compose senior standardise safety process help research team world design undertake clinical trial physician scientist make decision put patient safety clinical research monitor quality safety control appropriately product quality assurance monitor product safety issue ensure safety research essential create new well rd employee train good clinical reporting adverse event ongoing key focus research team review medicine transform life conduct practice work clinical research product usage benefitrisk evaluation gsk product trial patient healthy volunteer regularly audit trial site development market assess potential new medicine continue party carry trial behalf internal risk advisory panel encourage monitor efficacy safety approve ensure high ethical quality safety standard share information good practice progress overview progress clinical trial conduct highest conduct audits business ethical standard place datum summary implement patient safety comprehensive programme manage outsourced activity include training conduct clinical trial country partner gsks policy practice medicine likely suitable wide community gsk conduct clinical explore use technology trial investigational medicine country well understand patient adherence medicine know outset intent clinical trial include electronic pursue registration medicine reminder improve patient adherence trial available use country regimen sophisticated technology transmit data dose medication release stomach help scientist understand medication usedgsk responsible business supplement behaviour rigorous patient consumer safety continue manufacture supply combat risk counterfeit product introduce fingerprint endtoend produce billion pack counterfeit medicine vaccine supply chain serialisation programme apply medicine million dose vaccine healthcare product pose significant threat unique serial fingerprint product nearly billion pack consumer patient consumer safety strengthen anticounterfeite healthcare product year lack necessary active ingredient quality measure help protect patient consumer control deliver health benefit claim unique identifier record wellestablishe internal framework contain impurity actually database product scan place ensure compliance consistency cause harm verify database point reliability quality culture put patient supply chain end packaging centre effort deliver right time counterfeit gsk product originate china line site serialisation capability simplify rationalise colombia india pakistan peru implement fingerprint additional process remove risk affect quality counterfeit product include sensodyne line enable product track aquafresh toothpastes medicine endtoend supply chain model government report augmentin panadol standardise improve control counterfeit crime work closely entire supply chain manufacture comprehensive global strategy appropriate law enforcement custom operation source raw material identify prevent counterfeit tailor agency combat largescale highly make product quality control packaging solution requirement specific market sophisticated counterfeiter sixyear transport customer technological feature hologram investigation conclude chinese court security seal complex background pattern ensure patient consumer convict imprison group counterfeiter packaging help patient consumer safety commitment high standard manufacture counterfeit gsk recognise genuine product avoid manufacture help drive progress medicine sale africa collaborate counterfeit use technology track monitor ultimate goal zero accident zero law enforcement agency colombia investigate sale counterfeit product defect zero waste health india pakistan lead raid arrest support fight fake campaign safety waste underground counterfeit factory global campaign raise awareness report case raid arrest gsk manufacture site cork danger counterfeit medicine advocate datum summary ireland ste foy canada receive government help stop counterfeit warn letter fda take comprehensive action resolve issuesgsk responsible business supplement behaviour minimise animal testing understand share develop new medicine vaccine encourage uptake rs recognise refine need check desire effect employee outstanding contribution clear standard process place ethical concern safe people use animal welfare silver animal ensure animal welfare office animal surround animal need assess affect interaction welfare award go individual welfare ethic strategy lead chief pathway organ tissue work show age animal veterinary medicine oversee humane research animal study body make animal test critical research profoundly affect experimental responsible use animal gsk continue provide vital research strategy result apply knowledge study conduct contractor supplier design study few animal need information adopt rs approach commonly reduce variability study group behalf adhere high biomedical industry replace animal standard animal welfare adopt finding explore obtain alternative research possible reduce number research animal quality assurance national centre rs animal study provide group assess method regulation precise information refine technique few animal organisation care welfare programme require test minimise pain improve welfare animal previous year few past seven year case contractor few nonrodent fail adopt recommendation medicine vaccine replace nonhuman primate commitment continuous improvement launch strategic initiative animal start follow site visit stop work potential reduce reliance clinical trial animal study european bioinformatics institute sanger institute change animal use vs index year look new way develop medicine human cell tissue vitro test individual cell culture tissue use computer simulation commitment rigorously challenge need instead animal possible animal study work minimise impact animal welfare investing reduce development alternative study share continue rigorously challenge animalbase datum need animal study focus rs example study multiple sclerosis scientist find change optic nerve proxy overall nerve progress overview progress degeneration instead study different stage disease multiple animal develop method track loss vision single animal n animal gsk facility n animal contractor behalf gsk figure normalise year datum formation glaxosmithkline datum include animal research conduct external contractor behalf datum unavailable gsk responsible business supplement behaviour address human right impact support un guiding commit uphold universal activity embargo country declaration human right core labour stakeholder concern read online principle business standard set international labour business operate country target human right organization gsk signatory sanction law cuba north korea publish detail online key un global compact iran sudan syria clear challenge work address issue include risk company operate independent thirdparty assessment human right impact market believe people gsk antibribery corruption handbook human right impact business identify seven priority area access health deny access medicine gsk policy prevent corrupt practice care air quality impact relate propellant regime operate country aim maintain standard documentation supply medicine vaccine country clinical trial standard employment practice gsk antibribery corruption guideline need wish purchase include patient safety product counterfeiting use party essential medicine sanction country thirdparty supplier commitment address un guide compliance applicable sanction export cloning technology stem cell research principle business human right work highlight potential improve control comply disclosure disclosure clinical trial information operation companywide risk management control requirement iran threat reduction supplier relationship use supplier continue syria human rights act regularly care welfare treatment animal address new global party look good address challenge role transgenic animal oversight programme supply country meet biomedical research need patient progress overview track identify need provide use nonhuman primate nhps support local market effectively implement privacy datum security discovery development medicine principle global policy equal global privacy principle require vaccine inclusive treatment employee employee supplier ensure counterfeit healthcare product work address great personal datum collect process collaboration communication training transfer store appropriately securely pharmacovigilance line legal requirement website criterion work public policy group summary bind corporate rule safeguard personally identifiable information global code practice promotion customer interaction code conduct clinical trial develop worldgsk responsible business supplement behaviour ethical interaction regularly interact public policy train relevant employee tax engage government policymaker update global policy grant donation business increasingly challenge political key multilateral agency professional ensure contribute tax system gsk member trade stakeholder association advocate policy protect society operate industry association primarily represent interest patient support provide information tax management commit pharmaceutical consumer product business example work principle policy understand vaccine business national regional appropriately ethically help advance policy spur innovation responsibility pay appropriate international level website accelerate pace medical breakthrough tax fully support effort ensure company transparently usa government st century list appropriately transparent cure initiative share good practice engage patient advocacy group tax affair manage universal mass vaccination strategy engage support patient group substantial business employment gain insight patient help develop authority national immunisation technical presence country globe product advocate policy well advisory group europe adriatic country pay significant tax include meet need commitment demonstrate gsk gsk register cost relate lobbying corporation business taxis interaction patient advocacy group eu transparency register support include funding staff training tax associate employee political stakeholder conduct federal lobbying register cost educational assistance collaboration time responsibility appropriately ethically transparently represent interest eu institution disease awareness prevention project shareholder financially efficient range outline gsk code practice deliver sustainable tax rate spend federal promotion customer interaction grant approach look align investment funding gsk exceed patient progress overview progress lobbying activity group annual revenue exert strategy country corporate political contribution undue influence promote product substantial economic activity employee choose provide organisation grant patient group government policy promote tax regime financial support political group individual publish attractive business investment candidate political action committee pay considerable tax uk patient advocacy leader summit pal pac federal election campaign act significant proportion global continue build relationship patient gsk employee pac contribute corporate function rd manufacturing advocate industry health policy expert state federal candidate activity locate include pal event hold portugal fund contribute federal corporation tax profit generate switzerland latvia germany japan serbia candidate fund indirect tax employment taxis slovenia issue include empower contribute candidate state office precise amount fluctuate year year community conduct patientcentred care advocacy effort work improve access healthcare promote annual report detail include run advocacy office brussels salarie appropriate thirdparty policy group highquality strategy patient advocacy tax payment read ac sn ofe cr ie tic oe ns er mav el ra sn hd ip c fo en es su l nin ag pc ro il ts e tx hc elu rd ae ns g etr pd ue b l ishe clearly define criterion guide selection discuss usa national pal approach tax website eu register change gsk adjust calculation group ensure share value regional pal event focus healthcare e e thtc eh u th se f en dtr eo rd au l c loti bo bn inf gn e rew g ie su te rr u tle hs f fir g uh e r coe vg eis rt se tr h e cost align priority introduce cost quality pal reach salary benefit employee register lobby new standard operating procedure reflect leader country tu hs e gg oo vv ee rr nn mm ee nn tt flo fab irb sy fg fi cc eo n in u wlt aa sn ht ic gs tot n dre cse ar nc dh uru pn pn oin rtg taff criterion revise exist one begin include proportion gsk trade association fee govern interaction government official associate federal lobbyinggsk responsible business supplement people pulse programme employee opportunity use expertise support nonprofit organisation address major global health challenge building skill experience martin brandt volunteer ogra foundation kisumu kenyagsk responsible business supplement people approach ensure right talent engagement work hard attract develop engage employee mission strategy focus support people right skill retain skilled talented people need give gsk clear sense people integration support business level organisation track help drive business forward ceo achieve global target recruit student member corporate executive team announce propose threepart people strategy focus year early talent programme cet deliver regular live broadcast transaction novartis transaction area talent acknowledge global commitment message employee inform strengthen vaccine consumer increase apprentice population strategy progress recognise healthcare business result leadership performance decide include early talent importance listen employee act considerable change employee engagement community alongside future leader feedback improve experience novartis employee join graduate esprit postgraduate conduct interim survey cover business employee transfer place programme participant employee indicate manager country prioritie leadership lead people effectively employee leadership development programme engagement formal consultation limit number redundancy provide employee level skill employee representative union apply recruitment freeze need leader management work council particularly important costsave measure instance essential new management period restructure continue redundancy unavoidable advanced lead business work closely group commit offer support advice experienced leader coach programme help employee find new job information performance area help participant strengthen find datum summary provide clear regular communication leadership capability progress commitment hold live briefing local approach leadership leader ensure employee healthy workplace diversity employee performance volunteering cover follow page inform change affect briefing give improve way manage employee work council union employee performance promote individual open culture opportunity raise question responsibility accelerate delivery concern business strategy new global performance people accept system set clear objective people ensure successful cultural integration point develop align deliver strategy conduct interview senior leader underpin gsk expectation way suit organisation survey define require gsk individual capability gsk novartis employee put emphasis result understand perspective way result achieve choon business work culture enable well engage motivate marketing sale gsk singapore like future culture people strengthen connection participant future leader programme result develop cultural transformation plan individual performance rewardgsk responsible business supplement people approach continue create pipeline strong leader level business commit support experienced highpotential leader lead leader develop bestpractice business programme aim equip skill behaviour knowledge mindset require management capability value manage support diverse crosscultural base decision make highperforming team translate strategy integrate complementary range effective action business unit leadership programme month period participant undertake immersive experience mumbai london focus range leadership responsibility include build well programme clarify expect partnership create share value understand leader individually community key issue eg access medicine give deliver strategy help patient participant firsthand visibility ngo work customer feel well live long key teaching point leader work strengthen common language create paradox senior role eg balance local gsk leadership expectation leadership global need programme ensure exceptional small number leader demonstrate business diverse leader level business practise acuman leadership capability appoint inclusive leadership mean value draw corporate executive team direct differ knowledge perspective experience report invite participate highly customise style contain global community twoyear global learning experience bespoke management essential line leader enterprise leadership programme intense highly programme provide new manager thorough experiential programme combine assessment ground essential management responsibility coach training apply learn element eg performance management ensure introduce new programme enable confidently step career female leader enhance network clarify lead delivery programme help middle career ambition build confidence manager lead manager translate strong senior leader combine personal business strategy action drive performance group coach senior sponsorship open build capability enhance trust team honest dialogue believe programme help member colleague organisation well decision reduce risk increase innovationgsk responsible business supplement people protect health wellbee people progressive protect people continue reduce potential provide preventive healthcare progressive approach protect exposure employee hazardous groundbreake global partnership approach protect health wellbee employee substance example eliminate prevention pp programme aim create health wellbeing sustain strong health safety culture use formaldehyde fumigation healthy productive workforce operation important focus vaccine manufacturing process differentiate gsk employer pp offer people business past year information public policy position preventive healthcare service halve reportable injury illness hazardous chemical management immunisation cancer screening routine rate reduce figure eu reach regulation preventive examination employee incident hour work family little cost benefit build employee resilience mean achieve target package multinational company global energy resilience year early offer benefit scale commitment continue create work programme help employee environment inspire people grow health safety culture ensure employee build mental physical resilience year good progress perform healthy resilient way aware health safety risk lead happy healthy life home target implement pp globally stay safe work continue invest work programme pilot ecuador ghana leadership training help leader identify nigeria romania global workforce manage risk effectively implement middle east turkey progress overview track country participate global manufacturing supply leader pp provide preventive healthcare programme improve personal resilience country take employee family member research show participant experience country increase sustained improvement personal reportable injury illness rate employee family member country resilience wellbee long term hour work launch pp latin america south plan increase participation energy america early extend resilience programme roll pakistan countries africa business offer advice information counsel confidential employee assistance gsk approach promote energy programme support employee deal resilience novel wide range personal health wellbee innovative contribute professional issue stress financial health individual family problem employee access service line gsk proud work employee emphasise work field confidentiality service overcome social model cultural issue reluctant use professor sir cary cooper cbe distinguish professor organisational psychology health lancaster universitygsk responsible business supplement people promote inclusion diversity inclusive employer gender diversity disability cultural ethnic diversity aim improve gender balance level work hard ensure understand ensure leadership team represent value draw organisation focus create need people disability diverse market serve build different knowledge opportunity woman management develop employment opportunity talent pipeline include people range proportion woman management continue establish global disability council agree cultural ethnic background perspective experience increase chart woman priority set objective report progress nationality represent corporate working style continue represent corporate disability confident organisation executive team board people executive team board gsk employ emerge market asia pacific global workforce rank joint fifth uk government found member business disability japan represent workforce international bdi social enterprise involve report women representation board consumer healthcare business global business gsk help ftse company india pharmaceutical business latin develop global standard measure business america particularly good progress employeele womens leadership disability performance attract develop local talent initiative bring people addition effort global level commitment continue promote gsk senior leader global increase proportion people involve local initiative ensure inclusion diversity globally gsk conference encourage action emerge market participate recruitment process inclusive people accelerate women career development development programme join disability example company graduate mba accelerate difference female japan join accessible recruitment programme addition development progress overview progress manager complete individual group search engine call accessibility new regional headquarters singapore coaching session encourage disabled employee enable attract develop talent senior leader sponsor female manager emerge market develop local talent support career development uk help young people important focus africa strategy learn disability transition woman management position education employment project search svpvp partnership global director company computer aid inc danish manager company specialisterne start total recruiting people autism service team gsk responsible business supplement people community volunteering create change encourage people flagship pulse volunteer partnership encourage employee world enable employee work time support local community offer volunteer time nonprofit organisation charity pay day year volunteer expertise support month build leadership skill orange day programme orange day project provide valuable insight expertise include distribute food homeless community organisation work address major people malaysia organise career world healthcare challenge workshop unemployed parent poland maintenance work orphanage send employee india country work nonprofit provide million worth skilled extend employee volunteering bring service partner employee positive change community volunteer organisation establish new volunteer ambassador pulse volunteer partnership commitment extend volunteer pulse report network include employee watch video find opportunity bring positive country work nonprofit partner change community global health partner organisation volunteer understand need develop locally provide individual development agree pulse positive impact relevant programme raise nonprofit partner awareness opportunity differently result volunteer read online offer website volunteer agree pulse assignment strengthen progress overview progress awareness week leadership skill employee publish detail online key volunteering section website blog issue include pulse impact pulse assignment hazardous chemical management employee key global able recognise leverage gsk reach partnership save child collaborative problemsolve launch campaign skill ve gain year gsk employee country raise million lawyer gsk experience match funding gsk pulse change realise employee second work offer professional skill save child support partnership charity community partner trish assistant general counsel work philadelphia education fund usgsk responsible business supplement planet recover waste site singapore produce electricity steam power jurong site tomas hong yean work cut carbon emission waste costsgsk responsible business supplement planet approach commit climate change world gsk recognise vast reduce environmental press issue major threat people majority environmental impact focus reduce health global economic development environmental impact business occur outside impact operation impact like extreme weather heat wave affect food production availability clean operational control work closely change way antibiotic product water sanitation threaten hardwon look way save energy reduce water supply chain gsk show global health improvement impact waste improve yield reduce real leadership take meaningful cost whilst maintain efficacy resource efficiently action sustainability drive drug achieve reduction collaborate tackle antibiotic carbon footprint pack challenge reduce cost change help company past year increase production enhance competitiveness improve performance volume set ambitious goal reduce carbon innovation collaboration site irvine scotland water waste value chain introduce wind turbine combine tom delay source raw material impact heat power plant reduce carbon lab factory use disposal ceo carbon trust emission energy use product patient consumer instal anaerobic digester save gsk signatory un caring climate retain position cdps ftse site million year change mean irvine produce initiative un ceo water mandate climate disclosure leadership index product energy partnership seventh year gsk water share knowledge resource tackle pharmaceutical company include reduction carbon emission global environmental challenge index recognition quality climate change datum disclose quality road site singapore recertifie gsk remain use penicillin produce irvine pharmaceutical company achieve amoxicillin widely prescribe carbon trust carbon standard water antibiotic introduce new process standard cut carbon emission water enzyme eliminate chlorinate solvent use operation globally cut waste produce reduce carbon emission site solvent waste recover fuel generate electricity steam jurong factory singapore reduce water site worthe uk formulate year year package antibiotic augmentin amoxicillin clavulanic acid put tablet foil blister strip instead reduce foil use pack size enable pack palletgsk responsible business supplement planet approach continue set ambitious target achieve carbon understand carbon footprint value chain neutral value chain raw material operation logistic product use disposal work supplier invest aim minimise carbon product establish inhaler reduce impact technology efficiency emission transport particularly propellantbase recycling programme associate source raw measure renewable product customer inhaler generate carbon engage patient reduce material explore energy reduce carbon sea freight emission use emission associate way use resource emission energy air redesign patient consumer disposal product efficiently product use operation packaging transportation efficient tonne coe annum tonne coe annum tonne coe annum tonne coe annum tonne coe annum use meter energy dose inhaler tonne coe annum tonne coe annum hfa process use emission product tonne coe annum tonne coe annum business travel tonne coe annum total emission sale force estimate tonne co e annum tonne co e annumgsk responsible business supplement planet carbon reduce operational performance operational impact change way manufacture reduce scope emission reduce energy use carbon emission metereddose inhaler site spain carbon emission operational boundary associate generating energy france reduce propellant engage supplier million tonne coe purchase important focus programme purge air flixotide seretide reduction compare achieve cut environmental impact ventolin inhaler reduce patient cut emission continue investment energy efficiency invest infrastructure wind turbine ghg emission associate process associate source generate renewable energy waste tonne co e year scope emission associate fuel energy example ireland innovation recognise ceo raw material use logistic business travel patient use instal metre wind turbine cut environment health safety sustainability meter dose inhaler use hfa cork site electrical carbon footprint award product propellant increase save energy cost overall increase compare singapore instal boiler tackle scope emission continue fuelled waste jurong quality challenge sale propellantbase road site provide steam jurong site inhaler continue grow cut energy cost commitment reduce overall carbon product impact footprint vs work carbon trust scope ghg emission scope ghg emission carbonneutral value chain measure certify carbon tonne coe tonne coe footprint big selling product identify effective reduction emission associate progress overview work product example change process manufacture active pharmaceutical ingredient abacavir treat hiv reduce product carbon footprint target target gas fuel purchase material electricity steam product logistic propellant emission manufacture inhaler business travel air sale force travel propellant emission use inhaler emission use product exclude biogenic emission year accord disposal product current guidance account decrease emission estimate datagsk responsible business supplement planet carbon continue supply chain gsk ask want complete cycle working supplier help reduce complete cycle initiative encourage energy reduction workshop carbon emission critical achieving patient customer return old ill honest sceptical carbon goal collect carbon respiratory inhaler participate pharmacy water waste datum actually deliver send recycle large material supplier cover glad agree reduce waste send landfill billion spend raw material change make result prevent remain propellant manufacturing rd inhaler release greenhouse gas approach responsible procurement workshop reduce energy collect crush can launch gsk supplier use significant aluminum recycle scheme innovation exchange online forum inroad operating cost create opportunity pharmacist supplier collaborate share talk patient manage year practical idea improve energy efficiency use product condition pilot way share reduce water use supplier definitely worth use product meter dose information inhaler collect local insight improvement operation inhaler account carbon emission healthcare service provider help inform head engineering value chain carbon patient education reduce medicine waste offer run workshop select aesica pharmaceuticals trust certify carbon footprint supplier site help identify launch complete cycle respiratory product accord way reduce energy use run country greenhouse gas accounting sector guidance community hospital pharmacy participate recognise supplier effort reduce pharmaceutical product medical uk environmental impact new device footprinte compare relvarbreo gsk supplier environmental sustainability ellipta seretide accuhaleradvair diskus award packaging supplier alba dry powder inhaler seretide evohaler scheme create new supply gsk tube advair hfa metereddose inhaler opportunity pharmacist talk toothpaste award comprehensive result thoughtful energy efficiency programme patient manage design newer dry powder ellipta inhaler contain relvarbreo reduce carbon condition pilot way footprint day treatment share information inhaler versus old inhaler share collect local healthcare service product footprint uk nhs national formulary denmark help inform patient education reduce medicine wastage nikki yate head uk pharmaceuticalsgsk responsible business supplement planet water work reduce performance operational impact operational water use year year cut operational water use use million water water impact associate million reduction year operation research product baseline mean meet target laboratory manufacture site office cut operational water use year early systematically audit site identify opportunity cut water use measure reduce wide water impact audit high water use site value chain india italy singapore use challenge area water scarcity cut wateruse commitment reduce water complete extensive assessment identify average site activity high water impact impact value chain example introduce water efficient value chain prioritise effort vs cleaning procedure identify repair mapping water impact value chain leak invest efficient equipment water consumption dimension reduce water use remain important progress overview progress w bea ete nr wim op rka ic not g wiv te hr e xh te e rp na l e xw po e ry te ar ns w ne g ha ov se factor develop tool ta rg e carbon trust determine wide water identify factor contribute total impact site begin water impact pilot tool site globally include use product water scarcity freshwater site india significant water impact estimate gsk value chain available basin relation demand generate water impact score tool water impact consumer use clearly identify site main impact product particular people leave tap local water quality level pollution offer guidance help improvement run clean tooth freshwater source threat plan place extend turn tap campaign biodiversity result include add logo label sensodyne release pharmaceutical operation supply chain toothpaste brand uk supply chain use estimate health social risk people access million water raw material horlick clean water improve sanitation carbohydrate sugar wood derive product regulatory reputational risk level egg account water impact water governance regulatory risk relate partner teri ngo india water develop diagnostic water impact tool combine indicator water identify opportunity consumption datum wwf water large supplier reduce water risk filter develop global water impact impact work supplier tool identify hotspot teri extend process value chain suppliersgsk responsible business supplement planet waste goal halve performance australia example increase operational waste generate goal halve operational waste ethanol recover port fairy site operational waste thousand tonne actively eliminate reuse recycling litre reuse ethanol washing waste generate energy waste process maintain product quality generate tonne waste save business adopt simple operation year operating cost step eliminate reuse continue continue look innovative way reduce explore way cut waste individual site recycle generate help achieve target halve recycle waste site world example receive regulatory approval operational waste energy waste compost tonne year egg waste order priority total waste go landfill generate manufacturing flu vaccine site achieve zero waste sainte foy site canada instead send landfill status bring total site landfill egg waste mixed represent manufacture green waste sell compost major research development site commitment new idea find beneficial use recognise work waste include send package waste commitment reduce achieve zero landfill site total waste generate thousand tonne poznan site poland construction change way report waste long operational waste vs operational waste material waterproof floor running include solvent waste recycle reuse site total waste generate recognise need continue reduce pilot recover aluminium waste waste business grow toothpaste tube site maidenhead uk process use manufacture medicine progress overview work complex highly regulated multiple government globe read online year introduce major change improve manufacturing process reduce publish detail online key hazardous chemical management waste generate issue include ozone depletion metereddose inhaler avoid produce waste climate change asthma recognise waste value aim avoid send waste landfill genetically modify microorganism pharmaceutical environment disposal positive benefit environment health safety ehs use ozone deplete substance ancillary instead focus move waste gsk reach plant equipment hierarchy seek opportunity reuse gsk convention biological diversity green chemistry greener process lab possible recycling incinerate generate energy start gsk public policy nanotechnology assurance statement progress proportion waste recycle dispose positive benefit increase gsk responsible business supplement datum summary health note community investment global community investment million million million million strengthen healthcare system reinvestment ldc million million million million neglect tropical disease albendazole tablet donation lf elimination soiltransmitte helminth million million million million behaviour note compliance employee discipline policy violation employee dismiss agree leave company voluntarily document warning violation sale marketing policy subsequent dismissal breach external code number contact speak channel information clinical trial datum publicly available trial result summarie cumulative number clinical study report post register number trial list datum available request number research team approve data request access gsk trial datum dec clinical research clinical quality assurance assessment audits investigator site conduct gsksponsore trial audits gsk process audits contract research organisation carry clinical trial behalf audits gsk local operating company involve clinical trial activity investigation suspect irregularity inspection gsk site regulatory authority anticounterfeite number report case counterfeit number raid law enforcement agency regulatory authority number arrest law enforcement agency regulatory authority gsk responsible business supplement datum summary continue people note number injury illness lose time losttime injury illness rate hour work reportable injury illness rate hour work number nearmiss incident nearmiss incident report globally datum relate result pilot project global manufacturing supply number fatality fatality occur employee motor cycle hit suv carry overtake manoeuvre talent leadership development number leader complete lead delivery programme total number coach assignment number graduate recruit previously report combine figure number employee complete postgraduate esprit programme previously report combined figure number apprentice recruit inclusion diversity percentage woman management total percentage employee emerge market asiapacific japan volunteer number employee complete pulse datum restate actual datum available replace estimate datum report previouslygsk responsible business supplement datum summary continue planet datum note carbon scope ghg emission tonne coe estimate datum gas fuel electricity steam propellant emission manufacture inhaler sale force travel emission exclude biogenic emission accord current guidance account decrease emission total scope ghg emission tonne coe purchase material estimate datum product logistic business travel air propellant emission use inhaler use product estimate data disposal product estimate datum total water net water consumption operation million cubic metre estimate net water use value chain million cubic metre waste total waste generate thousand tonne waste landfill thousand tonne compliance internal audits number environmental fine footnote environmental remediation spend million responsibility remove pollution contaminant soil surface ground water facility previously disposal site waste management company followup inspection upper merion site regulator discover waste tank instal comply local regulation result fine levy longevity noncompliance waste tank take service survey site confirm compliance regulation settlement fine pay hamilton site failure submit risk management plan storage use chloroform site cooperate epa resolve matter promptly submit viable plan memphis site selfdisclose error omission annual air emission result penalty levy upgrade air emission control system improve reporting procedure site ensure compliance upper providence site selfdisclose failure comply recordkeeping requirement penalty levy improved reporting procedure ensure compliancegsk responsible business supplement summary assurance statement bureau verita summary independent opinion recommendation gsk response assurance assurance statement result verification conduct pleased bureau verita finding report bureau verita uk limit engage scope work bureau verita opinion gsk establish process manage gsk plc provide independent assurance gsk ehs performance datum ehs datum commit continue report performance annually environment health safety ehs improve ultimate goal provide report commitment provide fair summary ehsrelated performance datum accurate ehs datum public open transparent activity performance prepare gsk plc objective bureau website continue business activity responsible business verita work express opinion contain performance metric information work improve data accuracy cover annual report accuracy reliability ehs datum base establish collection emphasis incorporate data coverage provide summary finding collation process deem recommendation provide bureau datum report relate gsk free significant error omission bias verita implementation new assurance statement find global operation calendar year reporting system see improvement include detail scope work quality datum evidence site state datum report area business methodology finding recommendation consolidated level see base datum environment health datum responsible business improvement date recently implement datum safety section independently supplement site improve summary scope methodology management system eh central management ehs programme verify bureau veritas brand name assessment performance datum contain support process guidance continue work site appear italic report ehs datum table associate implementation ehs central improve data submission include trademark own andor license datum management process involve comprehensive effective provide comment explanation gsk associate company detail review integrity select refinement ehs reporting trend complete timely fashion reporting standard dataset aggregation check inclusion complete ehs data index global reporting process corporate level commercial operation business initiative guideline show element sample datum source gsk review support guidance fully meet cover report signatory site site choose represent requirement new system completion un global compact publish annual significant impact gsk operation revise approach detection communication progress demonstrate geographical spread anomalie consolidate ehs dataset uphold principle interview senior ehs staff statement independence impartiality feedback count understand gsk objective approach competence welcome feedback datum management bureau verita independent professional responsible business performance service company specialise quality report contact environmental health safety social csrcontactgskcom request accountability year history receive regular update progress assurance team extensive experience environmental social ethical health safety information system process bureau veritas code ethic ensure staff member avoid conflict interest maintain high ethical standard business activity london february